NCT01073644View on ClinicalTrials.gov

Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients

TerminatedOBSERVATIONAL
Enrollment

3

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

Sunitinib malate

sunitinib 50 mg, 4 weeks on, 2 weeks off

Trial Locations (2)

Unknown

Chong Hua Hospital, Cebu City

Private Clinic, Manila

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01073644 - Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients | Biotech Hunter | Biotech Hunter